Back to top
more

Alvotech (ALVO)

(Delayed Data from NSDQ)

$8.79 USD

8.79
285,304

-0.27 (-2.98%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $8.78 -0.01 (-0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect

by Zacks Equity Research

ALVO preps for Q2 results as investors eye early U.S. traction for Simlandi and Selarsdi, plus pipeline progress.

Zacks Equity Research

Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues

by Zacks Equity Research

RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.

Zacks Equity Research

Wall Street Analysts See a 91.05% Upside in Alvotech (ALVO): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 91.1% in Alvotech (ALVO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Down 6.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Alvotech (ALVO)

by Zacks Equity Research

Alvotech (ALVO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

Wall Street Analysts Think Alvotech (ALVO) Could Surge 72.61%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 72.6% in Alvotech (ALVO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar

by Zacks Equity Research

Dr. Reddy teams up with Alvotech to co-develop and commercialize a biosimilar of MRK's Keytruda, aiming to expand its biosimilars footprint.

Zacks Equity Research

RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up

by Zacks Equity Research

Dr. Reddy's stock is up on encouraging fiscal fourth-quarter 2025 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.

Zacks Equity Research

New Strong Sell Stocks for April 25th

by Zacks Equity Research

ALVO, AMPY and ADV have been added to the Zacks Rank #5 (Strong Sell) List on April 25, 2025.

Zacks Equity Research

New Strong Sell Stocks for April 17th

by Zacks Equity Research

AIRS, XOM and ALVO have been added to the Zacks Rank #5 (Strong Sell) List on April 17, 2025.

Zacks Equity Research

RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar

by Zacks Equity Research

Dr. Reddy's inks collaboration deal with Bio-Thera to develop and commercialize proposed biosimilar candidates of J&J's Stelara and Simponi in Southeast Asia.

Zacks Equity Research

FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review

by Zacks Equity Research

Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgen's Prolia and Xgeva for review.

Zacks Equity Research

Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Liquidia Technologies (LQDA) delivered earnings and revenue surprises of -21.05% and 43.11%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Has Alvotech (ALVO) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Alvotech (ALVO) and Becton Dickinson (BDX) have performed compared to their sector so far this year.

Zacks Equity Research

Are Medical Stocks Lagging Alvotech (ALVO) This Year?

by Zacks Equity Research

Here is how Alvotech (ALVO) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Zacks Equity Research

Wall Street Analysts Believe Alvotech (ALVO) Could Rally 39.83%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Alvotech (ALVO) points to a 39.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Is Alvotech (ALVO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Alvotech (ALVO) and Twist Bioscience (TWST) have performed compared to their sector so far this year.

Zacks Equity Research

Are Medical Stocks Lagging CareCloud (CCLD) This Year?

by Zacks Equity Research

Here is how CareCloud, Inc. (CCLD) and Alvotech (ALVO) have performed compared to their sector so far this year.

Zacks Equity Research

Alvotech (ALVO) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Alvotech (ALVO) delivered earnings and revenue surprises of 226.67% and 5.63%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Eyenovia, Inc. (EYEN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Eyenovia (EYEN) delivered earnings and revenue surprises of 15.38% and 97.10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Medical Stocks Lagging Alvotech (ALVO) This Year?

by Zacks Equity Research

Here is how Alvotech (ALVO) and Atossa Genetics Inc. (ATOS) have performed compared to their sector so far this year.

Zacks Equity Research

Here's Why You Should Consider Buying Alvotech (ALVO) Stock

by Zacks Equity Research

Here, we discuss some reasons why buying Alvotech (ALVO) stock now may turn out to be a prudent move.

Zacks Equity Research

TEVA Stock Rises 135% in a Year: What's Driving the Recovery?

by Zacks Equity Research

TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.

Zacks Equity Research

Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar

by Zacks Equity Research

Dr. Reddy's (RDY) announces entering into a license and supply agreement with Alvotech to develop and commercialize the latter's biosimilar candidate, AVT03, to Prolia and Xgeva.

Zacks Equity Research

ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

scPharmaceuticals (SCPH) delivered earnings and revenue surprises of 20% and 6.17%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of 5% and 51.56%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?